상세 보기
Improvements in health-related quality of life (HRQoL) in the SUNMO study: Subcutaneous (SC) mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) vs rituximab, gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after at least one prior therapy
- Budde, Elizabeth;
- Westin, Jason;
- Zhang, Huilai;
- Maruyama, Dai;
- Rego, Eduardo M.;
- ... Kim, Won-Seog;
- 외 13명
Citations
WEB OF SCIENCE
0- 제목
- Improvements in health-related quality of life (HRQoL) in the SUNMO study: Subcutaneous (SC) mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) vs rituximab, gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after at least one prior therapy
- 저자
- Budde, Elizabeth; Westin, Jason; Zhang, Huilai; Maruyama, Dai; Rego, Eduardo M.; Hong, Huangming; Goto, Hideki; Fesler, Mark; Goodgame, Boone; Li, Zhiming; Olszewski, Adam; Ashby, Joan; Yin, Shen; Ead, Wahib S.; Janousek, Martin; Pham, Song; Batlevi, Connie L.; Wei, Michael C.; Kim, Won-Seog
- 발행일
- 2025-11-03
- 유형
- Meeting Abstract
- 저널명
- Blood
- 권
- 146